Diffuse-type gastric cancer: A different perspective

Authors

DOI:

https://doi.org/10.22516/25007440.1403

Keywords:

Gastric cancer, adenocarcinoma, pathology, carcinogenesis, review, precancerous conditions

Abstract

Introduction: Diffuse-type gastric cancer has traditionally been managed and treated like intestinal-type gastric cancer. However, the literature shows that diffuse-type gastric cancer differs from intestinal-type gastric cancer in several respects. While the incidence of intestinal-type gastric cancer has gradually declined, that of diffuse-type gastric cancer has remained stable or even increased. This article critically reviews selected aspects of diffuse-type gastric cancer, including its epidemiology, anatomical location, etiology, relationship with Helicobacter pylori and the gastric microbiome, as well as current considerations regarding its carcinogenesis and treatment.

Results: Intestinal-type gastric cancer is more closely associated with environmental factors, whereas diffuse-type gastric cancer is more strongly associated with CDH1 mutations. Clinically, diffuse-type gastric cancer is associated with a poor prognosis, affects younger individuals, particularly women, and exhibits reduced benefit from available therapies or the development of treatment resistance.

Conclusions: Diffuse-type gastric cancer differs from intestinal-type gastric cancer in its epidemiological, clinical, pathological, molecular, genetic, and anatomical characteristics. Further advances in understanding its pathophysiology and its pathological and molecular subgroups are needed to improve patient selection for different therapeutic strategies, including their combination  and sequencing.

Downloads

Download data is not yet available.

Author Biographies

Ricardo Oliveros Wilches, Instituto Nacional de Cancerología

Cirujano gastrointestinal. Asesor. Bogotá, Colombia.

Helena Facundo Navia, Instituto Nacional de Cancerología

Standardized comparison of open vs minimally invasive surgery in patients undergoing hepatectomy through the textbook outcome. Juanita Gonzalez-Fajardo, Helena Facundo, Marcela Nuñez & Oscar A Guevara. Journal of Gastrointestinal Surgery. 2025;29(8):102131.

doi: 10.1016/j.gassur.2025.102131. Epub 2025 Jun 24.

Cáncer gástrico: detección y prevención. Oliveros-Wilches R, Facundo-Navia H, Pinilla-Morales R, Bonilla A, Aguirre G. Revista. colomb. Gastroenterol. 2025;40(4):463-471.

https://doi.org/10.22516/25007440.1399

Consenso colombiano de tumores neuroendocrinos intestinales y síndrome carcinoide. Fierro Maya, L. F., Córdoba Carreño, C. P., Cuéllar-Cuéllar, A. A., Facundo Navia, H., Flórez Romero, A., González Clavijo, A. M., González Devia, D., Guevara Cruz, O. A., Rojas Camacho, J. G., Rojas Melo, L. J., Román González, A., Romero Rojas, A. E., Sánchez Castillo, J. O., & Tapiero Garcia, M. 2024. Revista Colombiana De Endocrinología, Diabetes &Amp; Metabolismo, 11(4).

https://doi.org/10.53853/encr.11.4.896

 

Carlos Eduardo Bonilla González, Centro de Tratamiento e Investigación sobre Cáncer (CTIC) – Luis Carlos Sarmiento Angulo

MD, MSc. Médico especialista en oncología clínica y medicina interna. Oncólogo clínico, jefe de unidad funcional clínica gastrointestinal en CTIC. Bogotá, Colombia.

 

Ana Deise Bonilla Castañeda, Instituto Nacional de Cancerología

Cirujana gastrointestinal. Bogotá, Colombia.

Gustavo Adolfo Aguirre Bermudez, Instituto Nacional de Cancerología

Cirujano gastrointestinal. Especialista. Bogotá Colombia.

References

Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-63. https://doi.org/10.3322/caac.21834

Marghalani A, Bin Salman T, Faqeeh F, Asiri MK, Kabel AM. Gastric carcinoma: insights into risk factors, methods of diagnosis, possible lines of management and the role of primary care. J Family Med Prim Care 2020;9(6):2659-63. https://doi.org/10.4103/jfmpc.jfmpc_527_20

Bergquist JR, Leiting J L, Habermann E B, Cleary SP, Kendrick ML, Smoot RL, et al. Early onset gastric cancer is a distinct disease worrisome trends and oncogenic features. Surgery 2019;166(4):547-55. https://doi.org/10.1016/j.surg.2019.04.036

Corso G, Santucci C, Toffolutti F, Pisa E, La Vecchia C, Serraino D. Trends in diffuse type of gastric cancer: focus on younger women. Eur J Cancer Prev. 2024;33(6):541-44. https://doi.org/10.1097/CEJ.0000000000000891

Ma J, Shen H, Kapesa L, Zeng S. Lauren classification and individualized chemotherapy in Gastric Cancer. Oncol Lett. 2016;11(5):2959-64. https://doi.org/10.3892/ol.2016.4337

Seeneevassen L, Bessède E, Mégraud F, Lehours P, Dubus P, Varon C. Gastric cancer: Advances in carcinogenesis research and new therapeutic strategies. Int J Mol Sci. 2021;22(7):3418. https://doi.org/10.3390/ijms22073418

Waldum HL, Sagatun L, Mjønes P. Gastrin and Gastric Cancer. Front Endocrinol (Lausanne). 2017;8:1. https://doi.org/10.3389/fendo.2017.00001

Waldum HL, Fossmark R. Types of Gastric Carcinomas. Int J Mol Sci. 2018;19(12):4109. https://doi.org/10.3390/ijms19124109

Ooki A, Yamaguchi K. The dawn of precision medicine in diffuse-type gastric cancer. Ther Adv Med Oncol. 2022;14:17588359221083049. https://doi.org/10.1177/17588359221083049

Korivi BR, Faria S, Aly A, Sun J, Patnana M, Jensen CT, et al. Intestinal and diffuse gastric cancer: a retrospective study comparing primary sites. Clin Imaging. 2019;56:33-40. https://doi.org/10.1016/j.clinimag.2019.03.002

Berdugo-Hurtado F, Martín-Lagos-Maldonado A, Martínez-Domínguez AP, Vidal-Vílchez B, Benavente-Fernández A. Linitis gástrica: un reto diagnóstico. Gastroenterología y Hepatología. 2020;45(5):375–6. https://doi.org/10.1016/j.gastrohep.2020.08.01

Koulis A, Buckle A, Boussioutas A. Premalignant lesions and gastric cancer: current understanding. World J Gastrointest Oncol. 2019;11(9):665-78. https://doi.org/10.4251/wjgo.v11.i9.665

Toh JWT, Wilson RB. Pathways of Gastric Carcinogenesis, Helicobacter pylori Virulence and Interactions with Antioxidant Systems, Vitamin C and Phytochemicals. Int J Mol Sci. 2020;21(17):6451. https://doi.org/10.3390/ijms21176451

Figueiredo C, Costa S, Karameris A, Machado JC. Pathogenesis of Gastric Cancer. Helicobacter. 2015;20 Suppl 1:30-5. https://doi.org/10.1111/hel.12254

Oue N, Sentani K, Sakamoto N, Uraoka N, Yasui W. Molecular carcinogenesis of gastric cancer: Lauren classification, mucin phenotype expression, and cancer stem cells. Int J Clin Oncol. 2019;24(7):771-78. https://doi.org/10.1007/s10147-019-01443-9

Machlowska J, Baj J, Sitarz M, Maciejewski R, Sitarz R. Gastric Cancer: Epidemiology, Risk Factors, Classification, Genomic Characteristics and Treatment Strategies. Int J Mol Sci. 2020;21(11):4012. https://doi.org/10.3390/ijms21114012

Stewart OA, Wu F, Chen Y. The role of gastric microbiota in gastric cancer. GUT Microbes 2020;10(5):1220-30. https://doi.org/10.1080/19490976.2020.1762520

Assumpção PP, Barra WF, Ishak G, Coelho LGV, Coimbra FJF, Freitas HC, et al. The diffuse-type gastric cancer epidemiology enigma. BMC Gastroenterol. 2020;20(1):223. https://doi.org/10.1186/s12876-020-01354-4

Ansari S, Gantuya B, Tuan VP, Yamaoka Y. Diffuse Gastric Cancer: A Summary of Analogous Contributing Factors for Its Molecular Pathogenicity. Int J Mol Sci. 2018;19(8):2424. https://doi.org/10.3390/ijms19082424

Wu JY, Lee YC, Graham DY. The eradication of Helicobacter pylori to prevent gastric cancer: a critical appraisal. Expert Rev Gastroenterol Hepatol. 2019;13(1):17-24. https://doi.org/10.1080/17474124.2019.1542299

Choi IJ, Kim CG, Lee JY, Kim YI, Kook MC, Park B, et al. Family History of Gastric Cancer and Helicobacter pylori Treatment. N Engl J Med. 2020;382(5):427-36. https://doi.org/10.1056/NEJMoa1909666

Piscione M, Mazzone M, Di Marcantonio MC, Muraro R, Mincione G. Eradication of Helicobacter pylori and Gastric Cancer: A Controversial Relationship. Front Microbiol. 2021;12:630852. https://doi.org/10.3389/fmicb.2021.630852

Ford A, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer: systematic review and meta analysis. Gut. 2020;69(12):2113-21. https://doi.org/10.1136/gutjnl-2020-320839

Li L, Yu Ch. Helicobacter pylori infection following endoscopic resection of Early Gastric Cancer. Biomed Res Int. 2019;2019:9824964. https://doi.org/10.1155/2019/9824964

Matsuzaki J, Tsugawa H, Suzuki H. Precision Medicine Approaches to Prevent Gastric Cancer. Gut Liver. 2021;15(1):3-12. https://doi.org/10.5009/gnl19257

Waldum H. Tumor Classification Should Be Based on Biology and Not Consensus: Re-Defining Tumors Based on Biology May Accelerate Progress, An Experience of Gastric Cancer. Cancers (Basel). 2021;13(13):3159. https://doi.org/10.3390/cancers13133159

Tahara E. Genetic pathways of two types of gastric cancer. IARC Sci Publ. 2004;(157):327-49.

Waldum H, Mjønes PG. Correct Identification of Cell of Origin May Explain Many Aspects of Cancer: The Role of Neuroendocrine Cells as Exemplified from the Stomach. Int J Mol Sci. 2020;21(16):5751. https://doi.org/10.3390/ijms21165751

Monster JL, Kemp LJS, Gloerich M, van der Post RS. Diffuse gastric cancer: Emerging mechanisms of tumor initiation and progression. Biochim Biophys Acta Rev Cancer. 2022;1877(3):188719. https://doi.org/10.1016/j.bbcan.2022.188719

Carneiro F, Huntsman DG, Smyrk TC, Owen DA, Seruca R, Pharoah P, et al. Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. J Pathol. 2004;203(2):681-7. https://doi.org/10.1002/path.1564

Goldenring JR, Nam KT. Oxyntic atrophy, metaplasia, and gastric cancer. Prog Mol Biol Transl Sci. 2010;96:117-31. https://doi.org/10.1016/B978-0-12-381280-3.00005-1

Ajani JA, D’Amico TA, Bentrem DJ, Corvera CU, Das P, Enzinger PC, et al. Gastric Cancer versión 2.202. NCCN Clinical Practice Guidelines in oncology. J Natl Compr Canc Netw. 2025;23(5):169-91. https://doi.org/10.6004/jnccn.2025.0022

Murphy G, Pfeiffer R, Camargo MC, Rabkin CS. Meta analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location. Gastroenterology. 2009;137(3):824-33. https://doi.org/10.1053/j.gastro.2009.05.001

Wu LW, Jang SJ, Shapiro C, Fazlollahi L, Wang TC, Ryeom SW, et al. Diffuse Gastric Cancer: A Comprehensive Review of Molecular Features and Emerging Therapeutics. Target Oncol. 2024;19(6):845-65. https://doi.org/10.1007/s11523-024-01097-2

Li P, Li Z, Linghu E, Ji J; Society of Digestive Endoscopy of the Chinese Medical Association, Colorectal Surgery Group of the Chinese Medical Association, et al. Chinese national clinical practice guidelines on the prevention, diagnosis, and treatment of early gastric cancer. Chin Med J (Engl). 2024;137(8):887-908. https://doi.org/10.1097/CM9.0000000000003101

Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2025 (7th edition). Gastric Cancer. 2026;29(2):271-99. https://doi.org/10.1007/s10120-025-01698-4

Dinçer B, Sağdıç MF, Olgun M, Karayiğit A, Dilek GB, Sarıdemir S, et al. Subtotal versus total gastrectomy for mid- and distal gastric poorly cohesive carcinoma: a retrospective controlled study. Front Oncol. 2025;15:1717678. https://doi.org/10.3389/fonc.2025.1717678

Boubaddi M, Teixeira Farinha H, Lambert C, Pereira B, Piessen G, Gualtierotti M, et al. Total versus subtotal gastrectomy for distal gastric poorly cohesive carcinoma. Ann Surg Oncol. 2024;31(2):744-52. https://doi.org/10.1245/s10434-023-14496-y

Li Y, Zhu Z, Ma F, Xue L. Gastric signet Ring Cell Carcinoma: Current Management and future Challenges. Cancer Manag Res. 2020;12:7973-81. https://doi.org/10.2147/CMAR.S268032

Jiménez Fonseca P, Carmona-Bayonas A, Hernández R, Custodio A, Cano JM, Lacalle A, et al. Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real world data from the AGAMENON National Cancer Registry. Br J Cancer. 2017;117(6):775-82. https://doi.org/10.1038/bjc.2017.245

Janjigian YY, Ajani JA, Moehler M, Shen L, Garrido M, Gallardo C, et al. First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial. J Clin Oncol. 2024;42(17):2012-20. https://doi.org/10.1200/JCO.23.01601

Rha SY, Oh DY, Yañez P, Bai Y, Ryu MH, Lee J, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(11):1181-95. https://doi.org/10.1016/S1470-2045(23)00515-6

Janjigian YY, Al-Batran SE, Wainberg ZA, Muro K, Molena D, Van Cutsem E, et al. Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer. N Engl J Med. 2025;393(3):217-30. https://doi.org/10.1056/NEJMoa2503701

Wainberg ZA, Kang YK, Lee KW, Qin S, Yamaguchi K, Kim IH, et al. Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial. Gastric Cancer. 2024;27(3):558-70. https://doi.org/10.1007/s10120-024-01466-w

Polom K, Marano L, Marrelli D, De Luca R, Roviello G, Savelli V, et al. Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer. Br J Surg. 2018;105(3):159-67. https://doi.org/10.1002/bjs.10663

Liu X, Choi MG, Kim K, Kim KM, Kim ST, Park SH, et al. High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features. Pathol Res Pract. 2020;216(4):152881. https://doi.org/10.1016/j.prp.2020.152881

Lian J, Zhang G, Zhang Y, Liu H, Zhang J, Nan P, et al. PD-L1 and HER2 expression in gastric adenocarcinoma and their prognostic significance. Dig Liver Dis. 2022;54(10):1419-27. https://doi.org/10.1016/j.dld.2022.01.128

Van Cutsem E, Bang YJ, Feng-Yi F, Xu JM, Lee KW, Jiao SC, et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer. 2015;18(3):476-84. https://doi.org/10.1007/s10120-014-0402-y

Shitara K, Xu RH, Ajani JA, Moran D, Guerrero A, Li R, et al. Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Gastric Cancer. 2024;27(5):1058-68. https://doi.org/10.1007/s10120-024-01518-1

Figura 1. Carcinoma de tipo difuso con un estroma fibroso prominente. Células en anillo de sello. Imagen cortesía del Dr. J. Mesa.

Published

2026-11-13

How to Cite

Oliveros Wilches, R., Facundo Navia, H., Bonilla González, C. E., Bonilla Castañeda, A. D., & Aguirre Bermudez, G. A. (2026). Diffuse-type gastric cancer: A different perspective. Revista Colombiana De Gastroenterología, 41(4), 488–498. https://doi.org/10.22516/25007440.1403

Issue

Section

Review articles

Altmetric

Escanea para compartir
QR Code
Crossref Cited-by logo
Article metrics
Abstract views2
Galley views0
PDF Views0
HTML views0
Other views0

Some similar items: